Alpine Immune Sciences, Inc. (ALPN) financial statements (2020 and earlier)

Company profile

Business Address 188 EAST BLAINE ST., SUITE 200
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4152816187
Cash and cash equivalents161182425
Short-term investments2442733762
Restricted cash and investments0    
Receivables000  
Prepaid expense000  
Deferred costs00   
Other undisclosed current assets10110
Total current assets:4254836288
Noncurrent Assets
Operating lease, right-of-use asset10
Property, plant and equipment21100
Intangible assets, net (including goodwill)  1  
Intangible assets, net (excluding goodwill)  1  
Restricted cash and investments000  
Other undisclosed noncurrent assets   00
Total noncurrent assets:121300
TOTAL ASSETS:5455856288
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities76143
Accounts payable22021
Accrued liabilities54000
Employee-related liabilities   22
Deferred revenue1
Debt021  
Deferred rent credit 0
Deferred revenue and credits0  
Other undisclosed current liabilities   32
Total current liabilities:98264
Noncurrent Liabilities
Long-term debt and lease obligation1624  
Long-term debt, excluding current maturities524  
Operating lease, liability11
Liabilities, other than long-term debt  0  
Deferred revenue and credits0  
Deferred tax liabilities, net 0  
Total noncurrent liabilities:1624  
Total liabilities:2510664
Stockholders' equity
Stockholders' equity attributable to parent, including:2945795583
Common stock   00
Additional paid in capital1179188236232
Accumulated other comprehensive income (loss)0(0)(0)(0)0
Accumulated deficit(88)(46)(9)(180)(149)
Other undisclosed stockholders' equity attributable to parent000  
Total stockholders' equity:2945795583
TOTAL LIABILITIES AND EQUITY:5455856288

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenue, net2  
Gross profit:212  
Operating expenses(45)(39)(17)(32)(23)
Operating loss:(44)(38)(15)(32)(23)
Nonoperating income2 7 0
Investment income, nonoperating1 7  
Other nonoperating income1    
Interest and debt expense(0)(0)(0)  
Loss from continuing operations before equity method investments, income taxes:(42)(38)(9)(32)(23)
Other undisclosed income from continuing operations before income taxes 11  
Loss from continuing operations before income taxes:(42)(37)(8)(32)(23)
Income tax benefit 00  
Net loss:(42)(36)(8)(32)(23)
Other undisclosed net income attributable to parent   0 
Net loss available to common stockholders, diluted:(42)(36)(8)(31)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(42)(36)(8)(32)(23)
Comprehensive loss:(42)(36)(8)(32)(23)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)00
Comprehensive loss, net of tax, attributable to parent:(42)(36)(8)(31)(23)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: